DHR vs REGN: fair value comparison
Danaher Corporation and Regeneron Pharmaceuticals, Inc. · Updated 2026-08-31
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, DHR currently sits closer to the top of our discount ranking. REGN carries the stronger quality grade.
| DHR | REGN | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $216.07 | $794.19 |
| 12-month range | $175.15–$230.40 | $577.90–$790.81 |
| Sector rank | #68 of 113 Healthcare | #70 of 113 Healthcare |
| Quality grade | B | A |
| Momentum grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: DHR fair value analysis · REGN fair value analysis